{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:46:26Z","timestamp":1782279986335,"version":"3.54.5"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Programmed cell death protein 1 (PD-1) inhibitors have established a cornerstone in cancer therapy; however, there remains a lack of data regarding their use in people living with human immunodeficiency virus (HIV) infection (PWH), especially in patients with low CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell counts or baseline detectable HIV RNA. This study assessed the real-world efficacy and safety of PD-1 inhibitors in PWH presenting with concurrent malignancies, specifically capturing individuals with advanced baseline immunosuppression (CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell count &amp;lt; 100 cells\/\u03bcL,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a04) or with detectable HIV RNA (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a09).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From January 2022 to December 2024, patients diagnosed with cancer and treated with PD-1 inhibitors (camrelizumab, sintilimab, or tislelizumab) were enrolled. The included population was divided into an HIV-positive group and an HIV-negative group based on HIV status. Demographic details, clinical data, and cancer status were collected. Using propensity score matching (PSM) to adjust for baseline imbalances, we compared median progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (TRAEs) between the two groups. Cox regression analysis was conducted to evaluate the influence of multiple variables on treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From 90 enrolled patients (70 HIV-positive, 20 HIV-negative), PSM selected 56 (37 HIV-positive, 19 HIV-negative) for final analysis. The ORR and DCR were comparable between the HIV-positive and HIV-negative groups (16.2% vs. 15.8% and 51.4% vs. 47.4%, respectively). Median PFS was 11.5 months (95% CI: 6.8\u201316.2) for the HIV-positive group and 16.9 months (95% CI: Not evaluated (NE)\u201340.4) for the HIV-negative group. For the lung cancer subgroup, the ORR and DCR were 23.5% and 70.6% among 17 HIV-positive patients vs. 30.0% and 50.0% among 10 HIV-negative patients. The respective median PFS was 14.5 months (95% CI: 4.9\u201324.2) and 17.2 months (95% CI: NE\u201336.0). Multivariable Cox regression analysis confirmed that HIV status was not independently associated with PFS in the overall cohort. Among the four patients with low baseline CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell counts, the DCR was 25.0% (one stable disease [SD], three progressive disease [PD]). Among those with detectable baseline HIV RNA (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a09), four achieved SD and five experienced PD, yielding no objective responses. In the matched cohort, TRAEs were predominantly grades 1\u20132; severe (grade \u2265 3) toxicities occurred in three of 56 patients (5.4%), all within the HIV-positive group. Four patients\u2014all from the HIV-positive group\u2014discontinued immunotherapy due to TRAEs. HIV virological control was maintained without rebound throughout the study; overall CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell counts remained largely stable, with all patients presenting with baseline advanced immunosuppression (CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell count &amp;lt; 100 cells\/\u03bcL) demonstrating robust immune restoration by week 24.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This retrospective study indicated that PD-1 inhibitors are effective and generally well tolerated in PWH with concurrent malignancies. HIV status was not an independent prognostic factor for treatment outcomes, and robust immune restoration was achievable even in patients with advanced baseline immunosuppression. Although severe (grade \u2265 3) TRAEs and treatment discontinuations occurred exclusively within the HIV-positive cohort, overall toxicity rates remained low. Larger prospective studies are required to further validate these findings in patients with low CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell counts or unsuppressed viral loads.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1846602","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:47:43Z","timestamp":1782276463000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world efficacy and safety of PD-1 inhibitors in patients living with HIV and cancer: a retrospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaola","family":"Xue","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juyi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenpeng","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Center, Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojie","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Henan Infectious Diseases Hospital, the Sixth People\u2019s Hospital of Zhengzhou","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"B1","article-title":"The urgency of now: AIDS at a crossroads","volume-title":"The Urgency of Now: AIDS at a Crossroads","year":""},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2499","article-title":"Projected cancer incidence rates and burden of incident cancer cases in HIV-infected adults in the United States through 2030","volume":"168","author":"Shiels","year":"2018","journal-title":"Ann Intern Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV-infected population in the United States","volume":"103","author":"Shiels","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac925","article-title":"Age and cancer incidence in 5.2 million people with human immunodeficiency virus (HIV): The South African HIV Cancer Match Study","volume":"76","author":"Ruffieux","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3760\/cma.j.cn311365-20191125-00393","article-title":"Effects of combination antiretroviral therapy on acquired immunodefici -ency syndrome complicated with Malignant tumors","volume":"39","author":"Mo","year":"2021","journal-title":"Chin J Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181f53783","article-title":"Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users","volume":"55","author":"Shiels","year":"2010","journal-title":"J Acquir Defic Syndr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5967","article-title":"Elevated cancer-specific mortality among HIV-infected patients in the United States","volume":"33","author":"Coghill","year":"2015","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.06.036","article-title":"Colorectal cancer in HIV positive individuals: the immunological effects of treatment","volume":"47","author":"Alfa-Wali","year":"2011","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101613","article-title":"Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis","volume":"52","author":"Yuan","year":"2022","journal-title":"eClinical Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"986","DOI":"10.6004\/jnccn.2018.0066","article-title":"Cancer in people living with HIV, version 1.2018, NCCN clinical practice guidelines in oncology","volume":"16","author":"Reid","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B12","unstructured":"Eacs Guidelines(Version 12.0)\n          \n          2022"},{"key":"B13","doi-asserted-by":"publisher","first-page":"6661406\u201320","DOI":"10.1155\/2021\/6661406","article-title":"Current and future perspectives of PD-1\/PDL-1 blockade in cancer immunotherapy","volume":"2021","author":"Makuku","year":"2021","journal-title":"J Immunol Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(22)00116-7","article-title":"Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial","volume":"3","author":"Elbert","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34463","article-title":"A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma","volume":"128","author":"Munhoz","year":"2022","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00431-9","article-title":"First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial","volume":"12","author":"Zhong","year":"2024","journal-title":"Lancet Respir Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302044","article-title":"In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit","volume":"191","author":"Amancha","year":"2013","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001849","article-title":"Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency","volume":"32","author":"Evans","year":"2018","journal-title":"AIDS"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.5532","article-title":"Including persons with HIV infection in cancer clinical trials","volume":"26","author":"Persad","year":"2008","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13027-023-00512-z","article-title":"Use of programmed cell death protein 1 (PD-1) inhibitor therapy in HIV-infected patients with advanced cancer: a single-center study from China","volume":"18","author":"Wu","year":"2023","journal-title":"Infect Agents Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002883","article-title":"Safety and efficacy of PD-1 inhibitors in HIV-infected patients with severe comorbidities: a prospective observational cohort study","volume":"136","author":"Zhu","year":"2023","journal-title":"Chin Med J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.03.011","article-title":"Real-world multicenter study of PD-1 blockade in HIV-associated classical hodgkin lymphoma across the United States","volume":"24","author":"Lurain","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13080230","article-title":"Safety and efficacy of immune checkpoint inhibitors in human immunodeficiency virus-associated cancer: A systematic scoping review","volume":"13","author":"Alatawi","year":"2025","journal-title":"Diseases"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"B27","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0\n          \n          2017"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001447","article-title":"Human immunodeficiency virus\/acquired immunodeficiency syndrome prevalence, incidence, and mortality in China, 1990 to 2017: A secondary analysis of the global burden of disease study 2017 data","volume":"134","author":"Liu","year":"2021","journal-title":"Chin Med J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/apm.13020","article-title":"Cancer during HIV infection","volume":"128","author":"Neto","year":"2020","journal-title":"APMIS"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00640","article-title":"Cancer immunotherapy trials network 12: pembrolizumab in HIV-associated kaposi sarcoma","volume":"43","author":"Lurain","year":"2025","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009728","article-title":"Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study","volume":"12","author":"Assoumou","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2989048\u201352","DOI":"10.1155\/2019\/2989048","article-title":"Outcomes of programmed cell death protein 1 (PD-1) and programmed death-ligand 1(PD-L1) inhibitor therapy in HIV patients with advanced cancer","volume":"2019","author":"Bari","year":"2019","journal-title":"J Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study","volume":"6","author":"Cao","year":"2020","journal-title":"JAMA Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13256-018-1667-2","article-title":"Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report","volume":"12","author":"Li","year":"2018","journal-title":"J Med Case Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0342375","article-title":"Spatiotemporal aggregation and population distribution characteristics of HIV\/AIDS in Nanchang city: A monitoring analysis from 2012\u20132021","volume":"21","author":"Wang","year":"2026","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2025.077","article-title":"Evolving disease spectrum and characteristics of people with HIV in eastern China: a 12-year study","volume":"17","author":"Xiong","year":"2025","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B37","unstructured":"Notice of the National Healthcare Security Administration and the Ministry of Human Resources and Social Security on Issuing the National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalogue (2021 Edition)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/10732748231173475","article-title":"The efficacy and safety of tislelizumab as adjuvant treatment for advanced or metastatic bladder cancer in people living with HIV: A retrospective multi-center study","volume":"30","author":"Wu","year":"2023","journal-title":"Cancer Control"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02459","article-title":"Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: A real-world report from the cancer therapy using checkpoint inhibitors in people living with HIV-international (CATCH-IT) consortium","volume":"41","author":"Zarif","year":"2023","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ph18111654","article-title":"Evaluating the safety and efficacy of PD-1 inhibitors in HIV patients diagnosed with lung cancer:A systematic review","volume":"18","author":"Hetta","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1248790","article-title":"The safety and efficacy of PD-1 inhibitors in patients with advanced cancers and HIV\/AIDS in China","volume":"13","author":"Xiong","year":"2023","journal-title":"Front Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.53.082901.104024","article-title":"The challenge of viral reservoirs in HIV-1 infection","volume":"53","author":"Blankson","year":"2002","journal-title":"Annu Rev Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19072000","article-title":"Immune checkpoints as the immune system regulators and potential biomarkers in HIV-1 infection","volume":"19","author":"Sperk","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002298","article-title":"Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience","volume":"33","author":"Spano","year":"2019","journal-title":"AIDS"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-023-00518-y","article-title":"Camrelizumab for cancers in patients living with HIV: one-single center experience","volume":"20","author":"Wu","year":"2023","journal-title":"AIDS Res Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx696","article-title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","volume":"29","author":"Guihot","year":"2018","journal-title":"Ann Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08798-7","article-title":"PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+T cells from ART-suppressed individuals","volume":"10","author":"Fromentin","year":"2019","journal-title":"Nat Commun"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1846602\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:47:56Z","timestamp":1782276476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1846602\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":48,"alternative-id":["10.3389\/fonc.2026.1846602"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1846602","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"1846602"}}